A trial of combination antimalarial therapies in children from Papua New Guinea

New England Journal of Medicine

Volumn 359, Issue 24, 2008, Pages 2545-2557

  Karunajeewa, Harin A ^a   Mueller, Ivo ^b   Senn, Michele ^b   Lin, Enmoore ^b   Law, Irwin ^a   Gomorrai, P Servina ^b   Oa, Olive ^b   Griffin, Suzanne ^b   Kotab, Kaye ^b   Suano, Penias ^b   Tarongka, Nandao ^b   Ura, Alice ^b   Lautu, Dulcie ^b   Page Sharp, Madhu ^a   Wong, Rina ^a   Salman, Sam ^a   Siba, Peter ^b   Ilett, Kenneth F ^a   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ; DNA; FANSIDAR; PIPERAQUINE;

ARTICLE; BEDTIME DOSAGE; CHILD; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEVER; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REINFECTION; SIDE EFFECT; SPLENOMEGALY; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 57749116211     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0804915     Document Type: Article

References (40)

1. Feachem R, Sabot O. A new global malaria eradication strategy. Lancet 2008;371:1633-5.
2. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2006. (WHO/HTM/MAL/2006.1108.)
3. Müller I, Bockarie M, Alpers M, Smith T. The epidemiology of malaria in Papua New Guinea. Trends Parasitol 2003;19:253-9.
4. Genton B, al-Yaman F, Beck HP, et al. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity. Ann Trop Med Parasitol 1995;89:377-90.
5. Moir JS, Garner PA, Heywood PF, Alpers MP. Mortality in a rural area of Madang Province, Papua New Guinea. Ann Trop Med Parasitol 1989;83:305-19.
6. Cattani JA, Tulloch JL, Vrbova H, et al. The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am J Trop Med Hyg 1986;35:3-15.
7. Cox MJ, Kum DE, Tavul L, et al. Dynamics of malaria parasitaemia associated with febrile illness in children from a rural area of Madang, Papua New Guinea. Trans R Soc Trop Med Hyg 1994;88:191-7.
8. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007;77:Suppl:79-87.
9. Kitua AY, Smith TA, Alonso PL, et al. The role of low level Plasmodium falciparum parasitaemia in anaemia among infants living in an area of intense and perennial transmission. Trop Med Int Health 1997;2:325-33.
10. Standard treatment of common illnesses of children in Papua New Guinea. 7th ed. Port Moresby, Papua New Guinea: Papua New Guinea Department of Health, 2000.
11. Marfurt J, Mueller I, Sie A, et al. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg 2007;77:947-54.
12. Faye B, Ndiaye JL, Ndiaye D, Dieng Y, Faye O, Gaye O. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar J 2007;6:80.
13. Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2007;2(5):e20.
14. Mohamed AO, Eltaib EH, Ahmed OA, Elamin SB, Malik EM. The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether-lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan. Ann Trop Med Parasitol 2006;100:5-10.
15. Mukhtar EA, Gadalla NB, El-Zaki SE, et al. A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan. Malar J 2007;6:92.
16. Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007;369:757-65.
17. Zongo I, Dorsey G, Rouamba N, et al. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 2007;369:491-8. [Erratum, Lancet 2007;369:826.]
18. Tangpukdee N, Krudsood S, Thanachartwet W, et al. An open randomized clinical trial of Artekin vs artesunatemefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health 2005;36:1085-91.
19. Hutagalung R, Paiphun L, Ashley EA, et al. A randomized trial of artemetherlumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multidrug resistant Plasmodium falciparum on the western border of Thailand. Malar J 2005;4:46.
20. Smithuis F, Kyaw MK, Phe O, et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunatemefloquine in falciparum malaria: an open-label randomised comparison. Lancet 2006;367:2075-85.
21. Assessment and monitoring of anti-malarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization, 2003. (WHO/HTM/RBM/2003.50.)
22. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000;94:Suppl 1:S1-S90.
23. The WHO child growth standards. Geneva: World Health Organization, 2006. (Accessed November 14, 2008, at http://www.who.int/childgrowth/standards/en/.)
24. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg 2003;68:133-9.
25. Felger I, Beck HP. Genotyping of Plasmodium falciparum: PCR-RFLP analysis. Methods Mol Med 2002;72:117-29.
26. Karunajeewa HA, Ilett KF, Mueller I, et al. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother 2008;52:237-43.
27. Mansor SM, Navaratnam V, Yahaya N, Nair NK, Wernsdorfer WH, Degen PH. Determination of a new antimalarial drug, benflumetol, in blood plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996;682:321-5.
28. The international pharmacopoeia. 3rd ed. Vol. 4. Tests, methods, and general requirements: quality specifications for pharmaceutical substances, excipients, and dosage forms. Geneva: World Health Organization, 1994.
29. Makler MT, Hinrichs DJ. Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. Am J Trop Med Hyg 1993;48:205-10.
30. Dupont WD, Plummer WD Jr. Power and sample size calculations: a review and computer program. Control Clin Trials 1990;11:116-28.
31. Myint HY, Ashley EA, Day NP, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 2007;101:858-66.
32. Davis TM, Karunajeewa HA, Ilett KF. Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust 2005;182:181-5.
33. Basco LK, Ringwald P. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother 2003;47:1391-4.
34. Price RN, Hasugian AR, Ratcliff A, et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drugresistant malaria. Antimicrob Agents Chemother 2007;51:4090-7.
35. Sim IK, Davis TM, Ilett KF. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother 2005;49:2407-11.
36. Denis MB, Davis TM, Hewitt S, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis 2002;35:1469-76.
37. Hung TY, Davis TM, Ilett KF, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 2004;57:253-62.
38. Checchi F, Piola P, Fogg C, et al. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar J 2006;5:59.
39. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperaquine: a resurgent antimalarial drug. Drugs 2005;65:75-87.
40. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997;41:1413-22.